Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study.
Heumann P, Aguado-Barrera ME, Avuzzi B, Azria D, Briers E, Bultijnck R, Choudhury A, De Ruysscher D, Farcy-Jacquet MP, Fonteyne V, Gómez Caamaño A, Helmbold I, Johnson K, Kerns SL, Lambrecht M, Lingard Z, Rancati T, Rosenstein BS, Sperk E, Paul Symonds R, Talbot C, Valdagni R, Vega A, Veldeman L, Ward T, Webb A, West CM, Chang-Claude J, Seibold P; REQUITE Consortium. Heumann P, et al. Among authors: fonteyne v. Radiother Oncol. 2023 Jan;178:109426. doi: 10.1016/j.radonc.2022.11.015. Epub 2022 Nov 25. Radiother Oncol. 2023. PMID: 36442608 Free article.
Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P, Fonteyne V, De Neve W, De Gersem W, De Wagter C, Vandecasteele K, Duprez F, De Meerleer G. Ost P, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1286; author reply 1287. doi: 10.1016/j.ijrobp.2008.12.008. Int J Radiat Oncol Biol Phys. 2009. PMID: 19251105 No abstract available.
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P. Sundahl N, et al. Among authors: fonteyne v. J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3. J Transl Med. 2017. PMID: 28662677 Free PMC article. Clinical Trial.
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P, Strijbos M, den Mooter TV, Liefhooghe N, Bruwaene SV, Uvin P, Ghysel C, Ost D, Schatteman P, Bral S, Engels B, den Begin RV, Otte FX, Roumeguere T, Palumbo S, Neybuch Y, Fonteyne V, Ost P, Dirix L. Dirix P, et al. Among authors: fonteyne v. Future Oncol. 2020 Jun;16(16):1083-1189. doi: 10.2217/fon-2020-0056. Epub 2020 May 1. Future Oncol. 2020. PMID: 32356465
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: fonteyne v. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay.
Berghen C, Albersen M, Blanchard P, Bossi A, Briganti A, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G. Berghen C, et al. Among authors: fonteyne v. BJU Int. 2019 Jul;124(1):35-39. doi: 10.1111/bju.14686. Epub 2019 Feb 20. BJU Int. 2019. PMID: 30680874 Review. No abstract available.
Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Fonteyne V, et al. Radiother Oncol. 2007 Aug;84(2):156-63. doi: 10.1016/j.radonc.2007.06.013. Epub 2007 Aug 10. Radiother Oncol. 2007. PMID: 17692976
151 results